| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 114.32 | 15.8% | 28.2% |
| Total Income | 131.43 | 13.5% | 29.1% |
| Expenditure | 83.50 | 20.5% | 35.1% |
| PBT | 47.92 | 3.2% | 19.9% |
| Net Profit | 35.65 | 2.0% | 2.9% |
| OPM | 35.20% | 2.92pp | 2.34pp |
| NPM | 27.12% | 3.08pp | 8.95pp |
| EPS | 2.53 | 2.0% | 3.1% |
Growth masks margin pressure
Revenue surged 28% year-over-year but net profit fell 2.9%, as consolidated EBITDA margins compressed 300 basis points. Management attributes the gap to freight costs and project staffing — both claimed temporary — but the earnings miss suggests otherwise.
₹114.3 Cr
+28% YoY, +16% QoQ
36%
-300 bps QoQ from 39%
₹35.6 Cr
-2.9% YoY, NPM 27.1%
39%
stable, but consolidated diluted
The revenue print looks solid — 28% growth year-over-year, 16% quarter-on-quarter — but the bottom line tells a different story. Net profit fell 2.9% year-over-year despite the topline surge, and consolidated EBITDA margins compressed 300 basis points quarter-on-quarter to 36% from 39%. That gap is the quarter. Management blamed freight cost inflation and project staffing buildup, both claimed temporary. The call data suggests the margin pain runs deeper than management wants to admit.
Where the margin went
The core gases segment held its own at 39% margin (Q1: 38%), validating the underlying business. But consolidated EBITDA fell 300 bps because transportation costs spiked — diesel prices up, longer delivery routes — and employee expense jumped ₹11 million for project engineering buildup to support the BHEL contract. Management frames both as strategic investments in future execution capability. The numbers frame them as opex that offset topline gains.
Claims vs. what holds up
Revenue growth 28% YoY, 16% QoQ validates market demand and argan mix expansion.
Delivered ₹114.3 Cr (vs ₹89.2 Cr Q2 FY26, +28% YoY). H1 FY27 ₹2,130 Cr, +23% vs H1 FY26. Numbers check out.
Supported
Freight and power costs are temporary headwinds; expect normalization over next couple of quarters.
PAT declined 2.9% YoY despite 28% revenue growth. If freight/power were truly temporary, PAT should track revenue growth. The 2–3 month pass-through lag is material; recovery extends into H2, not Q3.
Overstated
Durgapur 325 TPD on-site plant commissioned in Q2 FY27, take-or-pay contract de-risks volume.
Facility operational towards end of September 2026. Q3 will be first full quarter. Contract structure verified. Milestone on track.
Supported
BHEL ₹480 Cr EPC contract awarded; validates engineering capability and coal gasification opportunity.
Contract confirmed September 2026, 8-quarter execution. Lower margins than core gases acknowledged but not quantified (single-digit to low-double digit implied). Strategic win, but margin dilution ahead.
Supported, with caveat
40%+ EBITDA margin aspiration remains on track for long-term.
Q2 delivered 36%, down 300 bps from Q1 39%. Management reframed as 'longer-term aspiration, not quarterly guarantee.' Current trajectory is compressing, not expanding.
Overstated
What changed on this call
Merchant plant timeline slipped six months. North India and West Central merchant plants (₹250 Cr capex for 450–500 TPD combined) originally guided to come online by end of FY27. Now expected H2 FY28, driven by land allotment and government approval delays. Capex amount unchanged, but incremental revenue contribution pushed out.
BHEL ₹480 Cr EPC contract awarded. Largest single project in company history. Odisha cryogenic air separation unit (1,200 TPD) execution over 8 quarters, revenue recognition Quarters 5–8 at earliest. Validates engineering capability but acknowledged to carry lower margins than core gases (single-digit to low-double digit range). Will be reported separately to allow investor comparison.
On-site plant execution validated. Durgapur 325 TPD commissioned on schedule (September 2026), 15-year take-or-pay contract. De-risks execution risk on this business model. Q3 FY27 will show first full-quarter benefit.
Capex guidance reaffirmed. ₹250 Cr FY27 and ₹200 Cr FY28 for merchant plant buildout unchanged, signaling management commitment despite timeline slip.
Street positioning — how the market reads this
The stock closed at ₹312.8, below its 20-day SMA (₹327.81) and 50-day SMA (₹339.77). From its all-time high of ₹637.7, it has fallen 50.95%. RSI sits at 44 — neutral leaning bearish. Relative to the 200-day moving average of ₹280.98, the stock holds above it, but momentum has turned decisively downward. The valuation repricing is sharp and recent.
Institutional ownership reflects selling pressure. FII holdings fell to 1.08% from 1.31% last quarter (−23 bps). Domestic institutions also trimmed, falling to 11.62% from 13.02% (−140 bps). Promoter ownership remains steady at 77.15%. The combination of a 50% drawdown from peak and continued institutional trimming suggests the market has already repriced earnings expectations downward and remains unconvinced on margin recovery near-term.
Revenue growth +28% YoY validates market demand and argan ramp
Durgapur 325 TPD on-site commissioned, de-risks new business model
₹480 Cr BHEL EPC contract confirms engineering capability at scale
Core gases margin stable at 39% — underlying business remains healthy
PAT fell 2.9% YoY despite 28% revenue growth — cost control deteriorating
EBITDA margin compressed 300 bps QoQ; freight/staffing headwinds persist
Merchant plant delays push capex benefit out 6+ months
EPC contracts carry single-digit to low-double digit margins; consolidated dilution ahead
FII and DII both selling; institutional confidence waning
Stock down 50% from peak; valuation compressed sharply
Risks, ranked by how much they should concern a holder
Margin recovery does not materialize; freight pass-through extends further
HighPAT already down year-over-year despite strong topline. If 2–3 month pass-through lag extends or customers resist price increases, margin compression persists beyond H2. Breaks confidence in guidance and jeopardizes full-year trajectory.
EPC margin dilution arrives faster than management models
HighBHEL ₹480 Cr (single-digit to low-double digit margin) begins revenue in Q3 FY28 at earliest. If execution ramps faster or incremental mix skews toward EPC, consolidated EBITDA margin falls below 40% target and persists through FY29.
Merchant plant delays extend further
Medium-highAlready slipped 6 months (FY27 end → H2 FY28) due to government approvals and land allotment. Further delays would push utilization ramp and incremental revenue beyond H2 FY28, eroding 2027 growth momentum.
Customer capex cycles deteriorate
MediumPeak utilization (₹800 Cr revenue target) depends on pharma, steel, healthcare capex recovery. If industrial capex softens, on-site plant utilization slows and merchant plant ramp extends, delaying profit inflection.
Argan pricing softens or global supply normalizes
MediumArgan mix uplift (10% → 16%) has driven margin benefit. Global market is tight, but if supply increases or demand softens, price support erodes and incremental margin dilutes.
1 · Q3 FY27 margin recovery
Will EBITDA margin expand back toward 39% as freight pass-through normalizes? This number validates or invalidates management's 'temporary headwinds' claim. If margin stays at 36% or below in Q3, the cost structure problem is structural, not cyclical.
2 · Durgapur ramp and utilization
Q3 will be first full quarter of Durgapur 325 TPD on-site operation. Track incremental revenue contribution, customer utilization trajectory, and pricing realization. Take-or-pay de-risks volume but contract terms drive economics.
3 · Merchant plant government approvals
Any update on land allotment and statutory approvals for North India and West Central plants? Reconfirmation of H2 FY28 timeline resolves delay uncertainty. Further pushouts would extend capex benefit beyond 2027 and weigh sentiment.
Ellenbarrie has delivered on its capacity strategy — Durgapur is live, BHEL ₹480 Cr contract validates engineering, and topline momentum is real at +28% year-over-year. But this quarter is steady execution, not a step-change. The margin compression and profit decline despite strong revenue growth signal that near-term opex headwinds (freight, staffing) are real and not yet normalized. Management's promise of 'temporary' cost pressure rings hollow when earnings are falling despite growth.
The stock has repriced sharply (down 50% from peak) and institutional flows are negative. At current valuations, the margin recovery story — not the revenue growth story — is what matters. If H2 FY27 delivers margin expansion and capex progress, the drawdown was an opportunity. If margins stay compressed, the sell-off has room to extend. The number to track from here is consolidated EBITDA margin. It's the deciding factor. Everything else is noise.
Margin compression offsets growth; capacity milestones on track
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
H1 FY27 guidance of 23% growth met (₹2,130 Cr realized). Capex plan reaffirmed. Merchant plant timeline slipped from FY27 end to FY28 end due to government delays—a miss on prior expectation, but capex numbers unchanged.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Ellenbarrie delivered 28% revenue growth and commissioned its first on-site plant (Durgapur 325 TPD) while securing a ₹480 Cr BHEL EPC contract, validating its capacity expansion strategy. However, consolidated EBITDA margins compressed 300 bps QoQ to 36% due to freight and employee cost headwinds, and PAT declined 2.9% YoY despite topline growth—signaling execution risk as capex ramps and lower-margin EPC revenues begin. Near-term margin recovery depends on successful pass-through of freight costs and utilization ramp; long-term upside is intact if 40%+ EBITDA aspiration is achieved via high-margin on-site scaling.
₹114.3 Cr
Revenue · +28.2% YoY₹35.6 Cr
Reported PAT · −2.9% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Revenue growth of 28% YoY, 16% QoQ in Q2 FY27
METDelivered ₹114.3 Cr (1,143 million), YoY +28%, QoQ +16% vs prior guidance of 20% core gas growth — higher due to argan/on-site contribution
EBITDA margin approximately 36% in Q2 vs 39% in Q1
METDelivered OPM 35.2%, NPM 27.1%; consolidated EBITDA margin fell 300 bps QoQ. Core gases segment margin 39% (vs 38% Q1), but consolidated diluted by transportation costs (+freight) and employee expense buildup for project team
325 TPD on-site plant in Durgapur commissioned in September 2026
METFacility became operational towards end of Q2, take-or-pay 15-year contract, Q3 FY27 expected to see full quarter benefit. Claim verified and timeline on track
₹480 Cr BHEL contract for 1,200 TPD air separation unit, execution over 8 quarters, commissioned FY29
METEPC award confirmed end of September 2026. 8-quarter execution implies Q3 FY28 start of revenue recognition. Margin will be lower than core gases (management declined to specify but acknowledged single-digit to low-double digit)
H1 FY27 revenue ₹2,130 million, 23% growth vs H1 FY26
METQ1 ₹987 million + Q2 ₹1,143 million = ₹2,130 million. YoY from H1 FY26 implied base ~₹1,732 million, delivering ~23% growth. Calculation checks out
Freight costs and power are temporary headwinds, expect normalization over next couple of quarters
OVERSTATEDManagement noted 2-3 month lag in pass-through for freight; power cost steady ~22% of revenue. PAT declined 2.9% YoY despite 28% revenue growth, indicating margin pressure is real and NOT yet normalized
Long-term 40%+ EBITDA margin target remains on track
OVERSTATEDQ2 delivered 36% (vs 39% Q1). Management reaffirmed as 'longer-term aspiration' but current trajectory is compressing, not expanding. Requires significant on-site mix shift and full utilization of high-margin capacity
Earnings quality
What changed since the last call
Merchant plant timeline slipped
DowngradeOriginally guided to come online FY27 end, now H2 FY28. Delay due to land allotment and government approvals. Capex amount (₹450 Cr) unchanged, timing set back ~6 months.
EBITDA margin guidance reaffirmed but near-term under pressure
Neutral40%+ long-term aspiration maintained, but Q2 delivered 36% vs prior quarter 39%. Management cited temporary freight/employee cost headwinds. Recovery timeline unclear.
On-site plant success de-risks EPC strategy
UpgradeDurgapur commissioning validates on-site execution. BHEL contract (₹480 Cr) awarded in Q2, proving capability to win larger EPC projects. Strategic moat strengthened despite margin dilution.
The Q&A
Analysts pressed hard on freight cost pass-through timing, BHEL EPC margins, and capex funding. Management was candid on 2-3 month pass-through lag and acknowledged EPC margins are 'significantly lower' than core business, but declined to quantify. On plant delays, management deflected to government approval timelines as external. Overall tone: confident on strategy, defensive on near-term margin pressure.
Freight cost pressure — Mohammad Uzair, Aveksat Financial Advisory
PartialPart of margin hit due to transportation cost. Long-term contracts allow cost pass-through to customers. We expect this to normalize over next couple of quarters.
Power cost exposure — Mohammad Uzair, Aveksat Financial Advisory
AnsweredPower was about 22% of revenue from sale of gases in both Q1 and Q2. Very minuscule portion of total revenue.
High-purity gas margins — Mohammad Uzair, Aveksat Financial Advisory
AnsweredYes, different product. Ultra high purity requires extra effort for quality analysis and certification. Much higher prices justified. Hydrogen electrolyzer is small business, used at Uluberia plant for ultra high purity oxygen/argon production.
Argon contribution & pricing — Mohammad Uzair, Aveksat Financial Advisory
PartialLong-term argon demand remains intact, high-margin product. Average realizations healthy. Prices remain healthy. Don't comment on quarterly realization. Long-term price trend remains positive.
EPC contract margins & long-term strategy — Nilang Jain, Green Gen Family Office
PartialEPC contracts carry lower margin than core gases business (no long-term capex required for latter). Project engineering revenue will be separate segment. Core gases margin to be tracked separately. We highlight this to avoid confusion. Focus remains on core gases for recurring revenue. EPC is complementary, opens room for future 1,000+ TPD on-site contracts.
Plant ramp-up & utilization timing — Pritesh Chheda, Lucky Investment Managers
PartialDurgapur: incremental revenue in H2, full quarter contribution from Q3 FY27. Uluberia 2: spare capacity available, revenue growth from both units. Expect 20% revenue growth on annualized basis from these two units. Peak utilization revenue across all assets: ₹450-500 Cr incremental → total ~₹800 Cr at full run rate. Timing: uncertain, depends on customer capex timelines and market conditions.
BHEL EPC execution and revenue recognition — Pritesh Chheda, Lucky Investment Managers
AnsweredAwarded September 2026. 24-month execution window reaffirmed in press release. Q1 FY29 start of execution assumed (Q3 of 8-quarter cycle). Larger revenue in Quarters 5-8. Revenue recognition follows actual project progress and accounting standards.
Cost pass-through lag quantification — Dikshi Jain, Incred Research
Answered2-3 months lag between cost increase and pass-through. Freight cost is pass-through, linked to diesel prices. Expect normalization over next couple of quarters.
Project engineering cost breakdown — Dikshi Jain, Incred Research
AnsweredAbout ₹11 million for the quarter. Investment into future execution capability for larger, more complex projects.
East India on-site plant commercials — Nilang Jain, Green Gen Family Office
AnsweredFixed amount we'll make every month. No ramp-up required. 15-year take-or-pay contract structure.
North & Central India merchant plant capex timeline — Dilakshi Jain, Incred Research (follow-up)
Answered6-8 quarters for merchant plant ramp-up. Both expected to come online in H2 FY28. Second half of next financial year (H2 FY28) for revenue contribution start.
Gas mix, industry sentiment, and long-term margin trajectory — Nilang Jain, Green Gen Family Office
PartialLong-term indicated 40% margin for gases segment (very close to current 39%). Argon contribution at 14-16%, trend to mid-teens. Expect this trend to continue. On-site revenue will meaningfully improve margin (higher margin than bulk). Pharma, healthcare, steel sentiment is encouraging. Implementation timelines slower than original but moving positive.
International expansion strategy — Darshil Jhaveri, Crown Capital
AnsweredCurrent focus is on India. Significant opportunities here at single-digit market share. Nothing imminent internationally at the moment.
Capex funding structure — Darshil Jhaveri, Crown Capital
AnsweredCurrently have cash on the books. Will take on some debt at project level. Nothing imminent in terms of capital raise.
Guidance
20% long-term core gases revenue growth
HighCore gases segment growing 27% YoY in Q2, above the 20% guided baseline. Driven by argan (10% → 16% mix contribution), on-site ramp-up, and customer capex recovery in pharma/steel/healthcare.
H1 FY27 revenue ₹2,130 million, +23% vs H1 FY26
HighDelivered as stated: Q1 ₹987 million + Q2 ₹1,143 million. Baseline H1 FY26 implied ~₹1,732 million.
Peak consolidated revenue ~₹800 Cr from current run rate ~₹400 Cr, when all merchant plants + on-site projects online
LowAspirational figure cited in Q&A. Assumes successful execution of ₹450 Cr capex (now delayed to H2 FY28), full Durgapur utilization, and BHEL execution in FY28-29. Timeline uncertain; management acknowledged 6-8 quarter ramp-up for merchant plants.
40%+ EBITDA margin, longer-term aspiration
MediumReaffirmed as longer-term target but clarified as 'aspiration, not quarterly guarantee'. Q2 delivered 36% (vs 39% Q1). Recovery depends on freight normalization, on-site mix shift, and utilization ramp. EPC contract dilution will persist through FY28-29.
Core gases segment margin to remain ~39-40% on long-term basis
HighQ2 delivered 39% (vs 38% Q1). Management confident in pricing power and operational efficiency of core business independent of consolidated headwinds.
Project engineering margin to be lower than core gases (single-digit to low-double digit range)
HighManagement explicitly acknowledged BHEL/EPC will carry margin profile significantly lower than core. This is accepted as strategic dilution for long-term positioning and cash flow generation (low balance sheet risk for EPC contracts).
FY27 capex ₹250 Cr for North India and West Central merchant plants (~450-500 TPD combined)
HighReaffirmed as 'on course' in Q2 call. Originally guided to complete FY27 end, now slipped to H2 FY28 due to land allotment and government approvals. Amount unchanged.
FY28 capex ₹200 Cr continuation for same merchant plant projects
HighReaffirmed alongside FY27 plan. No change in total budgeted capex.
Risks the call surfaced
Execution & capex delay
HighNorth India and West Central plants originally guided to FY27 end, now H2 FY28 (6-month slip). Government approvals and land allotment cited as external blockers. Further delays would push utilization ramp beyond H2 FY28, delaying ₹300 Cr incremental revenue impact.
Margin compression
HighQ2 EBITDA margin fell 300 bps QoQ to 36% despite 27% core gases growth. Freight costs up due to diesel price inflation; employee expense up ₹11 million for project engineering buildup. Management expects normalization over next 2 quarters, but PAT declined 2.9% YoY despite revenue growth, suggesting pass-through is lagging.
Margin dilution from EPC business
HighBHEL ₹480 Cr EPC contract carries 'significantly lower' margins than core gases (single-digit to low-double digit implied). As execution ramps in FY28-29 (8 quarters), incremental revenue from EPC will dilute consolidated EBITDA margin from the target 40%+ unless offset by high-margin on-site growth.
Customer concentration & capex cycle dependency
MediumRevenue growth depends on (a) customer-side capex recovery in pharma, steel, healthcare, and (b) timely ramp-up of new on-site/merchant plant capacity. If customer capex cycles extend beyond H2 FY28, utilization ramp and ₹800 Cr peak revenue target will slip further. Management acknowledged this uncertainty: 'It all depends on market situations...governments do not work at the speed of industry.'
Argan pricing volatility
MediumArgan contribution increased from 10% to 16% of gas mix, driving incremental margin uplift. Argan is a high-margin product but subject to global supply-demand cycles. Management noted 'long-term price trend remains positive' but declined to comment on quarterly volatility, suggesting pricing can fluctuate.
Management
Score 7/10. Clear on operational metrics and segment dynamics. Candid on freight and employee cost headwinds. Evasive on BHEL EPC margin specifics ('cannot comment'). Good depth in addressing argan pricing and on-site plant mechanics, but hedged on medium-term margin recovery timeline. Mixed track record. Delivered H1 FY27 revenue growth (23%, on guidance). Commissioned Durgapur on-site plant on schedule (September, within Q2). Delayed merchant plants by 6 months (government approval lag). Capex amounts reaffirmed. Overall: 2 wins, 1 timing miss, 1 large new win (BHEL ₹480 Cr).
1 · Q3 FY27
Durgapur on-site plant ramps to full quarter impact; incremental revenue expected Q3 onward
2 · H2 FY27
North India merchant plant (450-500 TPD) expected online per revised guidance; first capex output
3 · H2 FY27
West Central merchant plant expected ramp; freight cost pass-through should normalize by end of year
Near-term margin recovery depends on successful pass-through of freight costs and utilization ramp; long-term upside is intact if 40%+ EBITDA aspiration is achieved via high-margin on-site scaling.